

Invitation to presentation of Xbrane Biopharma's interim report January – September, 2021 on October 29, 2021.

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Friday October 29, 2021, at 10.00 a.m. CET. Xbrane will publish the company's interim report for January – September, 2021, on Friday October 29, 2021, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report for January - September 2021, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link:

<https://edge.media-server.com/mmc/p/xp3g5i77>

Confirmation Code: 1692076

Standard international: +44 (0) 2071 928 338

UK (Local): +44 (0) 844 481 97 52

UK (Tollfree): +44 (0) 800 279 66 19

Sweden (Local): +46 (0) 856 618 467

Sweden (TollFree): +46 (0) 20 012 51 60

US (Local): +1 646 741 31 67

US (TollFree): +1 877 870 91 35

Contacts

Martin Åmark, CEO

M: +46 76 309 37 77

E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR

M: +46 76 325 60 90

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilar candidates in its pipeline targeting € 7.9bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.

For more information, visit www.xbrane.com.

Attachments

[Invitation to presentation of Xbrane Biopharma's interim report January - September, 2021 on October 29, 2021.](#)